| A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder (NCT04155424) | Alexion Pharmaceuticals, Inc. | 2020-01-14 |
| Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy (NCT04170023) | Alexion Pharmaceuticals, Inc. | 2019-12-16 |
| An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD (NCT04201262) | Alexion Pharmaceuticals, Inc. | 2019-12-09 |
| Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) (NCT04202341) | Alexion Pharmaceuticals, Inc. | 2019-12-02 |
| A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants (NCT05254613) | Alexion Pharmaceuticals, Inc. | 2019-11-12 |
| Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa) (NCT04195763) | Alexion Pharmaceuticals, Inc. | 2019-11-06 |
| Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects (NCT04920370) | Alexion Pharmaceuticals, Inc. | 2019-09-04 |
| A Drug Interaction Study of Danicopan (NCT04709094) | Alexion Pharmaceuticals, Inc. | 2019-07-28 |
| Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults (NCT05303324) | Alexion Pharmaceuticals, Inc. | 2019-07-04 |
| Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor (NCT03661528) | Alexion Pharmaceuticals, Inc. | 2019-06-06 |
| Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis (NCT03920293) | Alexion Pharmaceuticals, Inc. | 2019-03-12 |
| Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab (NCT03748823) | Alexion Pharmaceuticals, Inc. | 2019-02-19 |
| A Study of Multiple Doses of ALXN2050 in Healthy Adults (NCT05047484) | Alexion Pharmaceuticals, Inc. | 2019-01-07 |
| US Selumetinib Registry (NCT05683678) | Alexion Pharmaceuticals, Inc. | 2019-01-04 |
| A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG) (NCT03759366) | Alexion Pharmaceuticals, Inc. | 2018-12-28 |
| A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults (NCT05109390) | Alexion Pharmaceuticals, Inc. | 2018-07-27 |
| A Study of the Cardiac Effects of Danicopan in Healthy Adults (NCT05016206) | Alexion Pharmaceuticals, Inc. | 2018-07-26 |
| Study Evaluating Betrixaban in Pediatric Participants (NCT03346083) | Alexion Pharmaceuticals, Inc. | 2018-07-13 |
| A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 (NCT03459443) | Alexion Pharmaceuticals, Inc. | 2018-06-20 |
| A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) (NCT03369236) | Alexion Pharmaceuticals, Inc. | 2018-06-12 |
| Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab (NCT03472885) | Alexion Pharmaceuticals, Inc. | 2018-05-08 |
| Study of Danicopan in Participants With Hepatic Impairment (NCT03555539) | Alexion Pharmaceuticals, Inc. | 2018-05-01 |
| Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease (NCT03403205) | Alexion Pharmaceuticals, Inc. | 2018-02-22 |
| A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (NCT03406507) | Alexion Pharmaceuticals, Inc. | 2018-02-22 |
| Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction (NCT04935294) | Alexion Pharmaceuticals, Inc. | 2018-01-24 |
| A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA) (NCT03075878) | Alexion Pharmaceuticals, Inc. | 2018-01-10 |
| A Study of Single-dose ALXN2050 in Healthy Adults (NCT05047458) | Alexion Pharmaceuticals, Inc. | 2017-11-28 |